■酒精性肝病(ALD)包括一系列肝脏疾病,包括肝脏脂肪变性,酒精性肝炎(AH),纤维化,肝硬化,和肝细胞癌(HCC)。microRNAs(miRNAs)作为ALD的潜在生物标志物已经引起了极大的兴趣。
■我们搜索了PubMed,Embase,从开始到2024年6月,WebofScience和Cochrane中央对照试验登记册(CENTRAL)系统。根据ALD的阶段对所有提取的数据进行分层。投票计数策略对miRNA表达谱进行了荟萃分析。
■我们纳入了40项研究。在饮酒个体的血清中与不饮酒,miRNA-122和miRNA-155上调,miRNA-146a下调。在ALD患者中与健康的控制,miRNA-122和miRNA-155也上调,miRNA-146a下调。然而,AH患者与健康的个体,只有血清miRNA-122水平上调。由于诊断准确性数据不足,我们未能得出miRNA区分ALD相关肝纤维化不同阶段的能力的结论.ALD相关HCC的结果也是不足和有争议的。
■循环miRNA-122是管理ALD个体最有希望的生物标志物。miRNA在ALD中的诊断准确性需要更多的研究。
■该协议已在国际前瞻性系统审查注册(PROSPERO)上注册(www.crd.约克。AC.英国/普适诺/),注册号为CRD42023391931。
UNASSIGNED: Alcoholic liver disease (ALD) encompasses a spectrum of liver conditions, including liver steatosis, alcoholic hepatitis (AH), fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). microRNAs (miRNAs) have garnered significant interest as potential biomarkers for ALD.
UNASSIGNED: We searched PubMed, Embase, Web of Science and Cochrane Central Register of Controlled Trials (CENTRAL) systemically from inception to June 2024. All extracted data was stratified according to the stages of ALD. The vote-counting strategy performed a meta-analysis on miRNA expression profiles.
UNASSIGNED: We included 40 studies. In serum of individuals with alcohol-use vs. no alcohol-use, miRNA-122 and miRNA-155 were upregulated, and miRNA-146a was downregulated. In patients with ALD vs. healthy controls, miRNA-122 and miRNA-155 were also upregulated, and miRNA-146a was downregulated. However, in patients with AH vs. healthy individuals, only the serum miRNA-122 level was upregulated. Due to insufficient data on diagnostic accuracy, we failed to conclude the ability of miRNAs to distinguish between different stages of ALD-related liver fibrosis. The results for ALD-related HCC were also insufficient and controversial.
UNASSIGNED: Circulating miRNA-122 was the most promising biomarker to manage individuals with ALD. More studies were needed for the diagnostic accuracy of miRNAs in ALD.
UNASSIGNED: This protocol was registered on the International Prospective Register of Systematic Reviews (PROSPERO) (www.crd.york.ac.uk/prospero/) with registration number CRD42023391931.